First Launch Of Lilly's Evista In USA
Eli Lilly has told the Marketletter that its once-daily selectiveestrogen receptor modulator Evista (raloxifene) has been made available in the USA, its first market, for the prevention of osteoporosis in postmenopausal women.
A spokeswoman for the company said that Evista was shipped on January 5 and was made available in pharmacies the same week at an average wholesale price of $1.65 per 60mg tablet.
Evista was one of a spate of US Food and Drug Administration approvals at the end of last year (Marketletter December 15, 1997), and its launch is expected to expand the osteoporosis market as a whole. Analysts consider Evista to be an extremely important drug for Lilly, and are predicting 1998 sales of around $200 million, rising to more than $1 billion in five years' time.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze